BioPharmSignal logoBioPharmSignal

Biotech News

New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology

Arcutis Biotherapeutics (ARQT)Arcutis Biotherapeutics2026-06-25 13:46 ESTSEC filing

Expert recommendations focused on the diagnosis and management of genital psoriasis across age groups including pediatric, adult, and older populations This is the second published manuscript from the Genital Psoriasis Wellness Consortium, a multidisciplinary group of expert clinicians Genital

Open original release

Related news

ARQTArcutis Biotherapeutics2026-06-25 13:46 EST

Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference

ARQTArcutis Biotherapeutics2026-06-25 13:46 EST

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ARQTArcutis Biotherapeutics2026-06-25 13:46 EST

Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update

ARQTArcutis Biotherapeutics2026-06-25 13:46 EST

Arcutis Management to Present at TD Cowen’s 46th Annual Health Care Conference

ARQTArcutis Biotherapeutics2026-06-25 13:46 EST

Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis

ARQTArcutis Biotherapeutics2026-06-25 13:46 EST

Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth

ARQTArcutis Biotherapeutics2026-06-25 13:46 EST

Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology

ARQTArcutis Biotherapeutics2026-06-25 13:46 EST

Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting

ARQTArcutis Biotherapeutics2026-06-25 13:46 EST

Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting

ARQTArcutis Biotherapeutics2026-06-25 13:46 EST

Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference

View all latest news

Arcutis Biotherapeutics

Arcutis Biotherapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

ARQTArcutis Biotherapeutics2026-06-26 08:47 EST

New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology

ARQTArcutis Biotherapeutics2026-06-26 08:47 EST

Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference

ARQTArcutis Biotherapeutics2026-06-26 08:47 EST

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ARQTArcutis Biotherapeutics2026-06-26 08:47 EST

Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update

ARQTArcutis Biotherapeutics2026-06-26 08:47 EST

Arcutis Management to Present at TD Cowen’s 46th Annual Health Care Conference

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States